Aegerion Pharmaceuticals Announces Issuance of Patent by European Patent
CAMBRIDGE, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, announced today the issuance by the European
Patent Office of Patent No. EP1725234 for a method of treating hyperlipidemia
or hypercholesterolemia, including severe hypercholesterolemia, using
step-wise, increasing doses of lomitapide. Aegerion's New Drug Application for
lomitapide is under review by the U.S. Food and Drug Administration and its
Marketing Authorization Application for lomitapide is under review by the
European Medicines Agency. Aegerion is seeking approval of lomitapide as an
adjunct to a low-fat diet and other lipid-lowering therapies to reduce
cholesterol in adult patients with homozygous familial hypercholesterolemia
The patent, entitled "Methods for Treating Disorders or Diseases Associated
with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects,"
describes the method of treating hyperlipidemia or hypercholesterolemia,
including severe hypercholesterolemia, by gradually titrating the doses of
lomitapide to increase the drug's desired activity, while managing the
tolerability profile for the patient. Such dosing regimens are an important
component of Aegerion's development of lomitapide as a potential treatment of
"This patent expands our intellectual property portfolio for lomitapide,"
commented Marc D. Beer, Chief Executive Officer of Aegerion."This issuance is
another important step in the development of lomitapide as a potential
treatment for HoFH in the European Union."
The patent expires in 2025. A corresponding patent issued in the United States
in April 2011.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on
the development and commercialization of novel, life-altering therapeutics to
treat debilitating and often fatal rare diseases. The company's lead drug
candidate, lomitapide, is in late-stage development for the treatment of
homozygous familial hypercholesterolemia (HoFH), a rare life-threatening
disease characterized by severely elevated cholesterol levels.
Aegerion is motivated by its commitment to patients first, as well as its core
values of integrity, innovation, responsibility to healthcare providers and
development of employees, with a constant focus on scientific and clinical
excellence. For more information, visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc.
VP, Investor Relations
Press spacebar to pause and continue. Press esc to stop.